Related Experiment Video
Updated: Mar 16, 2026
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Pulmonary Alveolar Microlithiasis
Atsushi Saito1, Francis X McCormack2
1Department of Biochemistry, Sapporo Medical University, School of Medicine, Sapporo 0608543, Japan; Department of Respiratory Medicine and Allergology, Sapporo Medical University, School of Medicine, Sapporo 0608556, Japan.
Abstract:
Pulmonary alveolar microlithiasis (PAM) is a genetic lung disorder that is characterized by the accumulation of calcium phosphate deposits in the alveolar spaces of the lung. Mutations in the type II sodium phosphate cotransporter, NPT2b, have been reported in patients with PAM. PAM progresses gradually, often producing incremental dyspnea on exertion, desaturation in young adulthood, and respiratory insufficiency by late middle age. Treatment remains supportive, including supplemental oxygen therapy. For patients with end-stage disease, lung transplantation is available as a last resort. The recent development of a laboratory animal model has revealed several promising treatment approaches for future trials.
Insights
Pulmonary alveolar microlithiasis (PAM) is a rare genetic lung disease causing calcium phosphate buildup. Research is exploring new treatments, with animal models showing promise for future clinical trials.
Area of Science:
- Pulmonary Medicine
- Genetics
- Rare Diseases
Background:
- Pulmonary alveolar microlithiasis (PAM) is a rare genetic lung disorder.
- Characterized by calcium phosphate deposits in lung alveoli.
- Associated with mutations in the NPT2b gene.
Purpose of the Study:
- To summarize the current understanding of Pulmonary alveolar microlithiasis.
- To highlight the natural progression and clinical manifestations of PAM.
- To discuss current and potential future treatment strategies.
Main Methods:
- Review of existing literature on Pulmonary alveolar microlithiasis.
- Analysis of genetic links, specifically NPT2b mutations.
- Examination of disease progression and patient outcomes.
Main Results:
- PAM is a progressive disease leading to dyspnea and respiratory insufficiency.
- Current treatments are primarily supportive, focusing on oxygen therapy.
- Lung transplantation is an option for end-stage disease.
Conclusions:
- Pulmonary alveolar microlithiasis requires ongoing research for effective therapies.
- Development of a laboratory animal model offers new avenues for treatment exploration.
- Future clinical trials are anticipated based on promising preclinical findings.
Related Concept Videos
01:26Alveoli and Alveolar Ducts
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...